249 related articles for article (PubMed ID: 28641483)
1. Good performance of platinum-based chemotherapy for high-grade gastroenteropancreatic and unknown primary neuroendocrine neoplasms.
Brandi G; Paragona M; Campana D; Brighi N; Bondi A; Pantaleo MA; Corbelli J; Barbera MA; Biasco G
J Chemother; 2018 Feb; 30(1):53-58. PubMed ID: 28641483
[TBL] [Abstract][Full Text] [Related]
2. Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3).
Ali AS; Grönberg M; Langer SW; Ladekarl M; Hjortland GO; Vestermark LW; Österlund P; Welin S; Grønbæk H; Knigge U; Sorbye H; Janson ET
Med Oncol; 2018 Mar; 35(4):47. PubMed ID: 29511910
[TBL] [Abstract][Full Text] [Related]
3. Irinotecan plus cisplatin followed by octreotide long-acting release maintenance treatment in advanced gastroenteropancreatic neuroendocrine carcinoma: IPO-NEC study.
Li J; Lu M; Lu Z; Li Z; Liu Y; Yang L; Li J; Zhang X; Zhou J; Wang X; Gong J; Gao J; Li Y; Shen L
Oncotarget; 2017 Apr; 8(15):25669-25678. PubMed ID: 27788498
[TBL] [Abstract][Full Text] [Related]
4. Evaluating bevacizumab in combination with FOLFIRI after the failure of platinum-etoposide regimen in patients with advanced poorly differentiated neuroendocrine carcinoma: The PRODIGE 41-BEVANEC randomized phase II study.
Walter T; Malka D; Hentic O; Lombard-Bohas C; Le Malicot K; Smith D; Ferru A; Assenat E; Cadiot G; Lievre A; Kurtz JE; Dahan L; Dubreuil O; Hautefeuille V; Lepere C; Gangloff A; Elhajbi F; Coriat R; Roquin G; Bouarioua N; Granger V; Scoazec JY; Lepage C
Dig Liver Dis; 2018 Feb; 50(2):195-198. PubMed ID: 29258812
[TBL] [Abstract][Full Text] [Related]
5. FOLFIRINEC: a randomized phase II trial of mFOLFIRINOX vs platinum-etoposide for metastatic neuroendocrine carcinoma of gastroenteropancreatic or unknown origin.
Hadoux J; Afchain P; Walter T; Tougeron D; Hautefeuille V; Monterymard C; Lorgis V; Thuillier F; Baudin E; Scoazec JY; Lepage C; Desgrippes R
Dig Liver Dis; 2021 Jul; 53(7):824-829. PubMed ID: 33994125
[TBL] [Abstract][Full Text] [Related]
6. Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications.
Fazio N; Milione M
Cancer Treat Rev; 2016 Nov; 50():61-67. PubMed ID: 27636009
[TBL] [Abstract][Full Text] [Related]
7. FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3.
Hentic O; Hammel P; Couvelard A; Rebours V; Zappa M; Palazzo M; Maire F; Goujon G; Gillet A; Lévy P; Ruszniewski P
Endocr Relat Cancer; 2012 Dec; 19(6):751-7. PubMed ID: 22940375
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin and etoposide as first-line chemotherapy for poorly differentiated neuroendocrine carcinoma of the hepatobiliary tract and pancreas.
Iwasa S; Morizane C; Okusaka T; Ueno H; Ikeda M; Kondo S; Tanaka T; Nakachi K; Mitsunaga S; Kojima Y; Hagihara A; Hiraoka N
Jpn J Clin Oncol; 2010 Apr; 40(4):313-8. PubMed ID: 20047862
[TBL] [Abstract][Full Text] [Related]
9. Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort.
Walter T; Tougeron D; Baudin E; Le Malicot K; Lecomte T; Malka D; Hentic O; Manfredi S; Bonnet I; Guimbaud R; Coriat R; Lepère C; Desauw C; Thirot-Bidault A; Dahan L; Roquin G; Aparicio T; Legoux JL; Lombard-Bohas C; Scoazec JY; Lepage C; Cadiot G;
Eur J Cancer; 2017 Jul; 79():158-165. PubMed ID: 28501762
[TBL] [Abstract][Full Text] [Related]
10. Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas.
Galleberg RB; Knigge U; Tiensuu Janson E; Vestermark LW; Haugvik SP; Ladekarl M; Langer SW; Grønbæk H; Österlund P; Hjortland GO; Assmus J; Tang L; Perren A; Sorbye H
Eur J Surg Oncol; 2017 Sep; 43(9):1682-1689. PubMed ID: 28522174
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Carboplatin and Etoposide Combination Chemotherapy for Extrapulmonary Neuroendocrine Carcinoma: A Retrospective Case Series.
Imai H; Shirota H; Okita A; Komine K; Saijo K; Takahashi M; Takahashi S; Takahashi M; Shimodaira H; Ishioka C
Chemotherapy; 2016; 61(3):111-6. PubMed ID: 26636658
[TBL] [Abstract][Full Text] [Related]
12. Carboplatin in Combination with Oral or Intravenous Etoposide for Extra-Pulmonary, Poorly-Differentiated Neuroendocrine Carcinomas.
Frizziero M; Spada F; Lamarca A; Kordatou Z; Barriuso J; Nuttall C; McNamara MG; Hubner RA; Mansoor W; Manoharan P; Fazio N; Valle JW
Neuroendocrinology; 2019; 109(2):100-112. PubMed ID: 30703770
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors of metastatic neuroendocrine carcinoma under first-line treatment with platinum etoposide with a focus on NEC score and Rb expression: Results from the multicentre RBNEC study of the Groupe d'Etude des Tumeurs Endocrines (GTE) and the ENDOCAN-RENATEN network.
Hadoux J; Kanaan C; Durand A; Hescot S; Hautefeuille V; Cadiot G; Tauveron I; Laboureau S; Do Cao C; Walter T; Petorin C; Blanchet O; Jannin A; Gu C; Faron M; Leteurtre E; Rousselet MC; Zakeyh JJ; Marchal A; Chatelain D; Beaulaton C; Hervieu V; Ducreux M; Scoazec JY; Baudin E
Eur J Cancer; 2021 Jul; 152():100-115. PubMed ID: 34090142
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Efficacy and Safety between Carboplatin-Etoposide and Cisplatin-Etoposide Combination Therapy in Patients with Advanced Neuroendocrine Carcinoma: A Retrospective Study.
Imai H; Saijo K; Kawamura Y; Kodera S; Komine K; Iwasaki T; Takenaga N; Kasahara Y; Ouchi K; Shirota H; Takahashi M; Ishioka C
Oncology; 2024; 102(5):359-367. PubMed ID: 37903486
[TBL] [Abstract][Full Text] [Related]
15. Current Treatment Options in Gastroenteropancreatic Neuroendocrine Carcinoma.
Thomas KEH; Voros BA; Boudreaux JP; Thiagarajan R; Woltering EA; Ramirez RA
Oncologist; 2019 Aug; 24(8):1076-1088. PubMed ID: 30635447
[TBL] [Abstract][Full Text] [Related]
16. Amrubicin monotherapy for patients with extrapulmonary neuroendocrine carcinoma after platinum-based chemotherapy.
Nio K; Arita S; Isobe T; Kusaba H; Kohashi K; Kajitani T; Tamura S; Hirano G; Mitsugi K; Makiyama A; Esaki T; Ariyama H; Oda Y; Akashi K; Baba E
Cancer Chemother Pharmacol; 2015 Apr; 75(4):829-35. PubMed ID: 25702050
[TBL] [Abstract][Full Text] [Related]
17. A Consensus-Developed Morphological Re-Evaluation of 196 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Its Clinical Correlations.
Elvebakken H; Perren A; Scoazec JY; Tang LH; Federspiel B; Klimstra DS; Vestermark LW; Ali AS; Zlobec I; Myklebust TÅ; Hjortland GO; Langer SW; Gronbaek H; Knigge U; Tiensuu Janson E; Sorbye H
Neuroendocrinology; 2021; 111(9):883-894. PubMed ID: 33002892
[TBL] [Abstract][Full Text] [Related]
18. Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system.
Yamaguchi T; Machida N; Morizane C; Kasuga A; Takahashi H; Sudo K; Nishina T; Tobimatsu K; Ishido K; Furuse J; Boku N; Okusaka T
Cancer Sci; 2014 Sep; 105(9):1176-81. PubMed ID: 24975505
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study.
Hainsworth JD; Spigel DR; Litchy S; Greco FA
J Clin Oncol; 2006 Aug; 24(22):3548-54. PubMed ID: 16877720
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy in gastroenteropancreatic (GEP) neuroendocrine carcinomas (NEC): a critical view.
Fazio N; Spada F; Giovannini M
Cancer Treat Rev; 2013 May; 39(3):270-4. PubMed ID: 22819619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
